Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0348 in Advanced Solid Tumors
NCT05718219Phase 1Terminated
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM0348 in solid tumor (4 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity at 28 days and Objective response rate at 2 years. Started Mar 2023; status: terminated.
02
Drugs
SIM0348
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05718219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718219.